Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

Infect Prev Pract. 2023 Mar;5(1):100267. doi: 10.1016/j.infpip.2022.100267. Epub 2022 Dec 30.

Abstract

Background: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of Novel coronavirus disease (COVID-19) due to occupational exposure is unknown.

Aim: To assess the risk of COVID-19 in healthcare workers with IBD.

Methods: A case control study enrolled 326 healthcare workers with IBD from 17 GETAID centres and matched non-healthcare workers with IBD controls (1:1) for gender, age, disease subtype and year of diagnosis. The study period was year 2020 during the COVID-19 outbreak.

Results: In total, 59 COVID-19 were recorded among cases (n = 32) and controls (n = 27), including 2 severe COVID-19 (requiring hospitalization, mechanic ventilation) but no death. No difference was observed between healthcare workers and controls regarding the overall incidence rates of COVID-19 4.9 ± 2.2 vs. 3.8 ± 1.9 per 100 patient-semesters, P = 0.34) and the overall incidence rates of severe COVID-19 (0.6 ± 7.8 vs. 0.3 ± 5.5 per 100 patient-semesters, P = 0.42). In multivariate analysis in the entire study population, COVID-19 was associated with patients with body mass index > 30 kg/m2 (HR = 2.48, 95%CI [1.13-5.44], P = 0.02).

Conclusion: Healthcare workers with IBD do not have an increased risk of COVID-19 compared with other patients with IBD.

Keywords: COVID-19, Novel coronavirus disease; CRP, C-reactive protein; Crohn's disease; Healthcare worker; IBD, inflammatory bowel disease; Inflammatory bowel disease; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor-alpha; UC, ulcerative colitis; Ulcerative colitis.